medconnect.in — The U.S. Food and Drug Administration has identified a new risk factor for progressive multifocal leukoencephalopathy, a life-threatening brain infection associated with the use of natalizumab, an immunomodulatory agent used to treat multiple sclerosis and Crohn’s disease.
Jan 24, 2012 View in Crawl 4
No comments yet
It's quiet in here... can you hear the echo?